Compare BLBX & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLBX | NXTC |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.7M | 49.0M |
| IPO Year | N/A | 2019 |
| Metric | BLBX | NXTC |
|---|---|---|
| Price | $12.20 | $12.84 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $23.00 |
| AVG Volume (30 Days) | ★ 91.4K | 31.5K |
| Earning Date | 10-16-2025 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,387,828.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.48 | $2.69 |
| 52 Week High | $17.75 | $15.74 |
| Indicator | BLBX | NXTC |
|---|---|---|
| Relative Strength Index (RSI) | 66.02 | 42.28 |
| Support Level | $9.70 | $11.57 |
| Resistance Level | $12.80 | $13.60 |
| Average True Range (ATR) | 1.03 | 1.11 |
| MACD | 0.20 | -0.21 |
| Stochastic Oscillator | 73.89 | 28.10 |
Blackboxstocks Inc is a financial technology and social media hybrid platform offering real-time proprietary analytics and news for stock and options traders of all levels. Its web-based software (the Blackbox System) employs predictive technology enhanced by artificial intelligence to find volatility and unusual market activity that may result in a rapid change in the price of a stock or option. It provides users with a fully interactive social media platform that is integrated into its dashboard, enabling users to exchange information and ideas quickly and efficiently through a common network. The company introduced a live audio/video feature that allows members to broadcast on their channels to share trading strategies and market insight within the Blackbox community.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.